Potential Opportunities of Modeling Bioavailability for Monoclonal Antibodies: An Overview of mAbs and the current challenges of mAb development

Abstract With a growing market size, and a large variety of applications, monoclonal antibody technology adoption and clinical usage is at an all-time high. This review article seeks to explore 10 monoclonal antibodies (mAbs) and their mechanism of action, specifically their pharmacodynamic (PD) and pharmacokinetic (PK) properties, and use a machine learning model with various parameters to assess whether the mAb has adequate bioavailability when delivered subcutaneously. This is an investigation of drug optimization and patient outcomes when transitioning from traditional IV administrations to subcutaneous injections. The machine learning model is an extension based on a paper by Han Lou and Michael Hageman, Machine Learning Attempts for Predicting Human Subcutaneous Bioavailability of Monoclonal Antibodies , where they took 10 mAbs and analyzed 45 different features. To further extend this paper, we took an additional 10 monoclonal antibodies that were delivered subcutaneously, and took into account their dosage concentration as an extension to traditional PK properties. By including additional mAbs and dosage, a more sophisticated model can be produced with high scalability to deep learning modalities.